360 filings
Page 5 of 18
8-K
3a0e232y99vavzpereqr
7 Aug 18
Dynavax Reports Second Quarter 2018 Financial Results
12:00am
8-K
kwbu sqsm1zs
5 Jun 18
Other Events
12:00am
8-K
ymerbwyi6wrsb46
1 Jun 18
Departure of Directors or Certain Officers
4:50pm
8-K
hi5w 91ri9h4hm7sbw
9 May 18
Dynavax Reports First Quarter 2018 Financial Results
4:10pm
8-K
yztf4wl2jm
26 Apr 18
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
4:10pm
8-K
o1stat0a3jtd4ka8fq
18 Apr 18
Other Events
12:00am
8-K
kftp76opwi0onm3 62
8 Mar 18
Dynavax Reports Fourth Quarter and Year End 2017 Financial Results
12:00am
8-K
cuyw2r
2 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
eytpfffv13bdtg6
22 Feb 18
HEPLISAV-B is the First and Only Two-Dose Vaccine in the U.S. for Hepatitis B Prevention in Adults
12:00am
8-K
oca1ki
20 Feb 18
Dynavax Secures $175 Million inNon-Dilutive Debt Financing
12:00am
8-K
inygv gek6eesn
9 Jan 18
Dynavax Announces HEPLISAV-B™ is Now Available in the United States
12:00am
8-K
rs3uwnfvvcp 5d20g5f2
5 Jan 18
Results of Operations and Financial Condition
12:00am
8-K
9rhunad06gw90n
30 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
f8msck
14 Nov 17
Entry into a Material Definitive Agreement
12:00am
8-K
vp6mluu
3 Nov 17
Dynavax Reports Third Quarter 2017 Financial Results
12:00am
8-K
up90wmo2iyx
1 Sep 17
Other Events
12:00am
8-K
owks3
10 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
lr7 2j7m185lxna2x95
7 Aug 17
Dynavax Provides U.S. Regulatory Update onHEPLISAV-B™ Following FDA Advisory Committee Meeting
12:00am
8-K
hser2l7aclgn434y
2 Aug 17
Dynavax Reports Second Quarter 2017 Financial Results
12:00am
8-K
47wksi4g1 hzmz8tlm
31 Jul 17
Dynavax Announces FDA Advisory Committee
12:00am